Clinical Trials Browser

Phase 3 × Carcinoma, Renal Cell × Nivolumab × Clear all

NCT07405164 2026-04-17

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT03055013 2026-04-13

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Phase 3 Active not recruiting

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03793166 2026-04-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT07000149 2026-03-10

eVOLVE-RCC02

Phase 3 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Phase 3 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03873402 2026-01-21

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT04810078 2025-10-09

CheckMate-67T

Phase 3 Active not recruiting

681 enrolled 3 FDA

Carcinoma, Renal Cell

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT04987203 2025-08-22

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Disease Progression

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 2 FDA

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 2 FDA

Carcinoma, Renal Cell

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03138512 2024-12-18

CheckMate 914

Phase 3 Completed

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01668784 2022-08-09

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Phase 3 Completed

821 enrolled 18 charts

Carcinoma, Renal Cell, Neoplasm Metastasis